Condition: Liver Transplantation (LT) · End-stage Liver Disease (ESLD) · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
The goal of the REFIL-2 study is to evaluate the effectiveness of a low splanchnic blood volume restrictive fluid management strategy (a strategy that involves limiting fluid administration and prioritizing the use of medications that raise blood pressure during surgery, combined with phlebotomy) in improving patients' recovery after surgery. The study compares the low splanchnic blood volume restrictive fluid management strategy to an optimized cardiac-output liberal fluid management strategy (which involves administering more fluids to raise blood pressure with less reliance on medications). Outcomes important to patients will be measured. This study (REFIL-2) had a vanguard phase (internal pilot) that included 138 patients (NCT05647733). The patients included in the vanguard pilot phase were not compared between groups but only analyzed descriptively using aggregated data. Only feasibility metrics were compared (see NCT05647733). These 138 patients were thus rolled into the REFIL-2 trial and included in the final sample size reported herein.
This description comes directly from the study's public registry record.
Manuela Mbacfou, MSc · 514-890-8000 · manuela.mbacfou.temgoua.chum@ssss.gouv.qc.ca
François Martin Carrier, MD · 514-890-8000 · francois.martin.carrier.med@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Vancouver General Hospital (VGH) | Vancouver, British Columbia, Canada | Recruiting |
| London Health Sciences Centre (LHSC) | London, Ontario, Canada | Recruiting |
| Centre hospitalier de l'Université de Montréal (CHUM) | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Centre (MUHC) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07695363